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became the putative factor associated with the increased occurrence of GBS among the vaccinees. The association of the vaccine and GBS was supported by the clustering of most of the cases in the second and third weeks after vaccination (17) .
To facilitate investigations of the mechanisms underlying the induction of neurological disease associated with swine influenza vaccines, we established an influenza vaccine-dependent animal model in rabbits which we have designated experimental allergic neuritis-like disease (EAN-LD). Experimental allergic neuritis (EAN) is a disease that can be induced in several species of laboratory animals by injecting tissue from the peripheral nervous system (PNS) or some of its components (4, 6, 21) . PNS dysfunction in EAN results from demyelination which occurs at sites characterized by infiltrates of lymphocytes into perivenular areas adjacent to nerve fibers and by the ultimate distortion and destruction of the myelin sheaths of peripheral nerves (2, 21) . The (2, 3) ; hence, EAN has been considered to be an animal model for GBS (2) . Each of the six lots of commercially produced vaccines was concentrated by lyophilization, and the inocula prepared for injection of each rabbit contained lipoidal materials ( 1.2 mg of cholesterol and 1.2 mg of EXPERIMENTAL ALLERGIC NEURITIS-LIKE DISEASE prepared in which the influenza vaccine was replaced with 0.5 mg of bovine serum albumin (BSA); additional controls consisted of mixtures in which influenza vaccine was included but the gangliosides were omitted.
Myelin. Myelin was prepared by a method described by Everly et al. (5) . Peripheral nerves were collected from rhesus monkeys. frozen in liquid nitrogen. and reduced to a fine powder with a mortar and pestle. Myelin was isolated by suspending the pulverized neural tissue in 0.32 M sucrose. layering the suspension on 0.85 M sucrose and centrifuging at 42.000 x g. In addition to the swine influenza-containing vaccines, two lots of whole-virion, trivalent, non-swine influenza vaccine, MSD-5006G and MSD-BoB, induced EAN-LD in six of eight and three of five rabbits, respectively. The total incidence (9 of 13) of EAN-LD in rabbits injected with mixtures containing whole-virion nonswine influenza vaccine was not significantly different (P = 0.29) from the incidence (12 of 14) of EAN-LD in rabbits injected with mixtures containing whole-virion swine influenza vaccine.
Controls for these trials consisted of two groups of rabbits which were examined regularly for signs of EAN-LD along with the vaccinetreated rabbits. One control group (13 Although this alternative mechanism is supported by the earlier observations of Nagai et al. (12) in which a neurological disease was induced by multiple injections, over an extended period, of gangliosides mixed with methylated BSA, egg lecithin, and FCA, this neurological disease was not produced in rabbits which received only a single injection of gangliosides mixed with adjuvants (13, 14, 20 Differences between our observations in rabbits and the occurrence of GBS in recipients of swine influenza vaccine in 1976 include the presence of FCA and gangliosides in the inocula which induced EAN-like disease in the rabbits. Likewise, the similar effects of swine influenza and non-swine influenza vaccines in the animal model appear to contrast with the human experience (8, 10) in which GBS was significantly associated with only vaccines containing swine influenza antigens. Our model, nevertheless, appears to offer a useful system for further investigation of the causes and mechanisms of GBS associated with influenza vaccines.
